Mereo BioPharma Group plc

The ultra-rare disease specialist Ultragenyx is approaching several important catalysts this year, including US Food and Drug Administration action on UX111 – the firm’s first gene therapy, which targ

British science is often held up as a shining light: both a source of national pride thanks to the country’s huge contributions in the past, and a crucial part of the economy which should help drive g

Ultragenyx Pharmaceutical Inc. unveiled positive 14-month data on 11 June from the Phase II portion of a potentially registrational trial of setrusumab in osteogenesis imperfecta (OI), which multiple

Sanofi has hit the acquisition trail again to strengthen its rare disease pipeline, buying US biotech Inhibrx, Inc. and what it hopes will be a best-in-class asset to treat alpha-1 antitrypsin defi